Aislinn Antrim, MA, Assistant Managing Editor

Selinexor demonstrated a 37% increase in probability that patients treated with the drug will be in remission at 12 months.

The majority of study participants demonstrated improvement of infraorbital hollows through 1 year.

Communication, flexibility, and virtual solutions will remain key as the COVID-19 pandemic continues.

Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.

Patients receiving brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in the frontline setting had a 41% reduction in the risk of death.

Being fully vaccinated was associated with a lower risk of requiring supplemental oxygen compared to being unvaccinated, as well as a lower risk of intensive care unit admission.

Children ages 5 to under 12 years received a 2-dose schedule of 10 µg each whereas children under age 5 received a lower 3 µg dose for each injection in the phase 2/3 study.

The novel CAR T cells can deliver a toxic drug payload directly to a tumor, killing tumor cells that contain the cancer marker and nearby cancer cells that do not.

In a clinical trial, the median annualized bleeding rates for all bleeds was reduced from a historical median of 5 to an on-study median of 2.3, which is a 54.7% reduction.

Although men are more likely than women to be admitted for a hypertensive crisis, women have similar hospital mortality rates.

The 2-dose Spikevax COVID-19 vaccine was approved by the FDA based on a comprehensive submission package including efficacy and safety data approximately 6 months after the second dose.

The pill molnupiravir and the intravenous drug remdesivir were just as effective against the omicron variant as they were against earlier strains.

The study also found conflicting feelings, as participants seemed overwhelmed by too many recommendations while simultaneously perceiving cancer as an unavoidable death sentence.

Omnipod 5 is the first tubeless automated insulin delivery system that integrates with the Dexcom G6 Continuous Glucose Monitoring System and a compatible smartphone.

Symptoms of depression were reduced as quickly as 1 to 4 hours after a single treatment and lasted up to 2 weeks.

The findings suggest that pregnant women should not delay COVID-19 vaccination until late pregnancy.

Women had lower health-related quality of life at the beginning of the study, although men experienced a more rapid decline over time.

A machine-learning method called XGBoost provided the highest overall accuracy, despite being the least complex model.

The 2 drugs are the first small molecule JAK-1 inhibitors to be approved in the United States as treatment options for patients who are not responding to other therapies.

Nearly two-thirds of respondents had residual feelings of anxiety, depression, or PTSD after using prescription medications.

Early-stage melanomas at risk of spreading secrete the TGFβ2 growth factor, which causes the downregulation of the AMBRA1 and Loricrin proteins.

The FDA also expanded the pediatric emergency use authorization for remdesivir to include the treatment of non-hospitalized pediatric patients at high risk of disease progression.

In a pair of pivotal studies, risankizumab-rzaa (Skyrizi) met the primary endpoint of American College of Rheumatology 20% improvement response at week 24 compared to placebo.

Researchers found similar improvements in dryness, redness, roughness, tightness, irritation, moisturization, smoothness, and overall skin appearance between the 2 products.

New trial results showed statistically significant improvements in overall survival and progression-free survival.

Clinical benefits were seen across subgroups, including patients with squamous and non-squamous lung cancer subtypes, and regardless of PD-L1 levels.

Finding alternative means to promote interleukin 25 could enhance the benefits of fecal transplants in patients with recurrent C. difficile infections.

IMX-110 is a tissue-specific therapeutic designed to accumulate at intended therapeutic sites at 3 to 5 times the rate of conventional therapeutics.

The phase 3 ARASENS trial is the only study prospectively designed to evaluate an androgen receptor inhibitor combined with docetaxel and androgen deprivation therapy in this patient population.

Oral apremilast achieved a clinically meaningful and statistically significant improvement in the primary endpoint of the modified static Physician’s Global Assessment of Genitalia response.